Adhansia XR™ (methylphenidate HCl) Extended-Release Capsules CII for the Treatment of ADHD

 Adlon Therapeutics L.P. Announces FDA Approval for Adhansia XR™ (methylphenidate HCl) Extended-Release Capsules CII for the Treatment of ADHD

via Business Wire Health: Clinical Trials News

STAMFORD, Conn.--(BUSINESS WIRE)--Adlon Therapeutics L.P., a subsidiary of Purdue Pharma L.P., announced that the U.S. Food and Drug Administration (FDA) approved Adhansia XR™ (methylphenidate hydrochloride) extended-release capsules CII, a central nervous system (CNS) stimulant, for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in patients six years and older. In a simulated Adult Workplace Environment (AWE) study, Adhansia XR demonstrated statistically significant improveme

Add tags (Currently: Clinical Trials)